EARLY ONLINE RELEASE

This article was posted on the Archives Web site as an Early Online Release. Note: Due to the extremely time sensitive nature of the content of this article, it has not been copyedited or formatted per journal style. Changes or corrections may be made to this article when it appears in a future print issue of the Archives. Early Online Release articles are citable by using the Digital Object Identifier (DOI), a unique number given to every article.

The DOI for this manuscript is doi: 10.5858/arpa.2021-0213-SA

The final published version of this manuscript will replace the Early Online Release version at the above DOI once it is available.

© 2021  College of American Pathologists
Evaluation of a Surrogate ELISA- Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation with IgG Commercial Serology Assays

Vijayalakshmi Nandakumar, PhD; Tracie Profaizer, MS; Bucky K. Lozier, MS; Marc G. Elgort, PhD; Erin T. Larragoite, MS; Elizabeth S.C.P Williams, MS; Antonio Solis-Leal, MS; J Brandon Lopez, BS; Bradford K. Berges, PhD; Vicente Planelles, PhD; Jenna Rychert, PhD; Patricia R. Slev, PhD; Julio C. Delgado, MS, MD

ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA (Nandakumar, Profaizer, Lozier, Elgort, Rychert, Slev, Delgado); Department of Pathology, University of Utah School of Medicine, Salt Lake City, Utah, USA (Nandakumar, Larragoite, Williams, Planelles, Rychert, Slev, Delgado); Department of Microbiology & Molecular Biology, Brigham Young University, Provo, UTAH, USA (Solis-Leal, Lopez, Berges)

Corresponding Author:
Julio C. Delgado, MS, MD
Institute for Clinical and Experimental Pathology
ARUP
500 Chipeta Way
Salt Lake City, UT 84108-1221
T: 801-583-2787x4256; julio.delgado@aruplab.com

Research Funding: Financial support for this work was provided by the Institute of Clinical and Experimental Pathology at ARUP Laboratories. cPass SARS-CoV-2 Neutralization Antibody Detection Kits were supplied by GenScript.

-Supplemental digital content can be found at the end of article.
- The authors have no relevant financial interest in the products or companies described in this article.
-Running title: Evaluation of SARS-COV-2 Serology Assays
ABSTRACT

**Context:** Emerging evidence shows correlation between the presence of neutralization antibodies (nAbs) and protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Currently available commercial serology assays lack the ability to specifically identify nAbs. An ELISA-based nAb assay (GenScript cPass neutralization antibody assay) has recently received emergency use authorization from the Food and Drug Administration (FDA).

**Objective:** To evaluate the performance characteristics of this assay and compare and correlate it with the commercial assays that detect SARS-CoV-2 specific IgG.

**Design:** Specimens from SARS-COV-2 infected patients (n=124), healthy donors obtained pre-pandemic (n=100), and from patients with non-COVID (coronavirus disease 2019) respiratory infections (n=92) were analyzed using this assay. Samples with residual volume were also tested on three commercial serology platforms (Abbott, EUROIMMUN, Siemens). Twenty-eight randomly selected specimens from patients with COVID-19 and 10 healthy controls were subjected to a Plaque Reduction Neutralization Test (PRNT).

**Results:** The cPass assay exhibited 96.1% (95% CI, 94.9%-97.3%) sensitivity (at >14 days post-positive PCR), 100% (95% CI, 98.0%-100.0%) specificity and zero cross-reactivity for the presence of non-COVID respiratory infections. When compared to the plaque reduction assay, 97.4% (95% CI, 96.2%-98.5%) qualitative agreement and a positive correlation (R² =0.76) was observed. Comparison of IgG signals from each of the commercial assays with the nAb results from PRNT/cPass assays displayed >94.7% qualitative agreement and correlations with R²=0.43/0.68 (Abbott), R²=0.57/0.85 (EUROIMMUN) and R²=0.39/0.63 (Siemens), respectively.

**Conclusions:** The combined data support the use of cPass assay for accurate detection of the nAb response. Positive IgG results from commercial assays associated reasonably with nAbs presence and can serve as a substitute.
INTRODUCTION

With the availability of vaccines against the highly pathogenic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and as the pressure to re-open the economy increases, the demand for COVID-19 (coronavirus disease 2019) antibody testing is speculated to increase. Although serological tests are not recommended for initial diagnosis, it has wide implications in contact tracing, diagnosis of asymptomatic infections, seroprevalence assessments, humoral immunity assessment for screening convalescent plasma donors, and for monitoring immune response in vaccinated individuals. The concept of presumptive immunity has long remained with infectious diseases and vaccines and its key component are the neutralization antibodies (nAbs). Neutralization antibodies are specific for the viral surface antigens that aids in the entry into a host cell. In SARS-CoV-2, these epitopes are predominantly located in the receptor binding domain (RBD) of the spike (S) protein. Several studies have implicated the benefits of nAbs to SARS-CoV-2 and protection from reinfection.

The current reference standard for detecting nAbs is the plaque reduction neutralization test (PRNT), or microneutralization test. These assays require the use of live viruses and in the case of SARS-CoV-2 require a biosafety level 3 (BSL3) containment facility and are technically difficult to perform. Alternatively, a pseudo type virus neutralization assay can be used as a substitute and performed under BSL2 conditions. Regardless, cell-based virus neutralization assays are cumbersome, associated with significant analytical variability and challenging to support in most clinical laboratories. The cPass neutralization antibody assay, an ELISA-based surrogate neutralization assay recently obtained Food and Drug Administration (FDA) Emergency Use Authorization (EUA) and is the first EUA for SARS-CoV-2 nAb antibody detection. The assay utilizes the purified protein components of the RBD and human angiotensin converting enzyme 2 (ACE2) interaction in a competitive ELISA based platform. The assay is easy to perform and can be automated on the immunoassay processing platforms for high throughput analysis.
In this study we evaluated the performance characteristics of the cPass neutralization antibody assay and compared it to the gold standard live virus PRNT assay. The commercial antibody assays measure both types of antibodies (binding and neutralizing) and do not discriminate nAbs specifically. However, these commercial platforms are more readily available in the clinical laboratories and are easy to implement. Previous studies have evaluated the correlation of the commercial serology assays with the SARS-COV-2 neutralization activity, as an indirect means to predict the presence of nAbs. These studies are based on cell-based viral or pseudoviral neutralization assays and have arrived at varying conclusions\textsuperscript{9, 10}. Herein, we evaluate for the first time whether the commercial IgG serology assays can predict the nAb activity with the same level of accuracy as the cPass assay. Results of a head-to-head comparison of the IgG antibodies measured using three commercial serology assays with the nAb activity detected by the cPass and PRNT assays demonstrate that the cPass assay exhibits a better accuracy in the qualitative and quantitative assessment of nAbs, however the commercially available IgG serology assays also correlated well with the nAbs presence qualitatively.

**MATERIALS AND METHODS**

**Samples**

A total of 124 samples collected from 81 individuals confirmed positive for SARS-CoV-2 infection by an FDA authorized reverse transcription polymerase chain reaction (RT-PCR) assay at ARUP Laboratories (Salt Lake City, UT), were used to evaluate clinical sensitivity. Samples were collected 0 to 36 days post-PCR testing. One hundred samples collected prior to August 2019, before the beginning of the COVID-19 pandemic, were used to evaluate clinical specificity. Of these, 80 were from adults (age range 20-68 years), and 20 were from pediatric patients (age range 2-18 years). Ninety-two samples collected from individuals with respiratory illnesses other than COVID-19 (n=74) as well as individuals positive for rheumatoid factor (n=12) and heterophile antibody (n=6), were used to assess
cross-reactivity (analytical specificity). All samples were collected, handled, and de-identified in accordance with an institutional review board (IRB) approved protocol.

**IgG Antibody Testing**

IgG antibody was evaluated on three different platforms and were performed following the manufacturer’s directions: Abbott SARS-CoV-2 IgG assay (antigen target: N), performed on the Abbott Architect i2000 (Abbott Laboratories Inc., Abbott Park, IL), the EUROIMMUN Anti-SARS-CoV-2 IgG ELISA Assay (antigen target: S), (EUROIMMUN US, Mountain Lakes, NJ), performed both manually and automated on the Dynex Agility (Dynex Technologies, Chantilly, VA), and the Siemens SARS-CoV-2 IgG assay (antigen target: RBD), performed on the ADVIA Centaur XPT (Siemens Medical Solutions, Malvern, PA).

**Neutralization Antibody Testing**

The cPass SARS-CoV-2 Neutralization Antibody Detection Kit (GenScript, Piscataway, NJ) was performed according to the manufacturer’s instructions. Briefly, patient serum was mixed with sample dilution buffer (1:10) and horseradish peroxidase conjugated recombinant SARS-CoV-2 receptor binding domain (HRP-RBD) fragments. The pre-incubation step allowed for the binding of circulating nAbs to the HRP-RBD. After 30 minutes at 37°C, the mixture was added to a capture plate which had been pre-coated with the ACE2 protein. Any unbound HRP-RBD or HRP-RBD bound to non-neutralization antibodies will be bound to the plate while the circulating neutralization antibody HRP-RBD complexes will remain in the supernatant and be removed during the wash step. After washing, tetramethyl benzidine substrate solution was added followed by the Stop Solution which quenched the reaction, turning the well color yellow. The plate was immediately read at 450 nm on a microtiter plate reader. Results were reported as percent inhibition in comparison to the negative control, with a cutoff of 30% indicating the presence of nAbs.

The PRNT assay was performed at Brigham Young University (Provo, UT) using the SARS-CoV-2 USA-WA1/2020 isolate (BEI Resources; Cat # NR-55281). First, replication competent virus was grown in Vero E6 cells before being stored at -80°C. A confluent monolayer of Vero E6 cells were then
plated in 12 well plates 24 hours before infection. Patient serum samples were serially diluted in DMEM for a final concentration of 1:25, 1:100, 1:400, and 1:1600 in DMEM. Once diluted, 200 plaque forming units (PFU) of SARS-CoV-2 virus was then added to the serum and incubated for one hour at 37°C to allow for neutralization to occur. After incubation, the mixture was added to the Vero E6 cells and incubated for one hour prior to removing the virus/serum mixture and rinsing the cells with 1 mL 1X phosphate-buffered saline (PBS). Top agar with 2X Dulbecco’s Modified Eagle Medium (DMEM) was then added to the cells and allowed to solidify. After the top agar solidified, the plate was incubated for 3 days at 37°C. Following incubation, cells were fixed with formaldehyde for one hour prior to removing the top agar. Cells were then stained with crystal violet and plaques were counted. Finally, neutralization titers (NT) were calculated for 50% neutralization (NT50) using GraphPad Prism (version 8.4.3).

**Statistical Analysis**

Statistical analysis was performed using Microsoft EXCEL, AnalyzeIT, version 5.66 (Microsoft corp., Redmond, Washington) and GraphPad Prism version 8.4.3 (Graphpad Software Inc., La Jolla, CA). Positive and negative cut points were adopted from the manufacturer’s package inserts. Sensitivity was calculated using the SARS-CoV-2 RT-PCR as the reference method and specificity was assessed using results from the healthy and other infection groups. The sensitivity and specificity for each of the commercial platforms was evaluated using the nAb values as the reference standard. Overall agreement was determined from the proportion of total positive and negative concordant results. Simple linear regression analysis was conducted to determine the correlation coefficients. The Area Under the Curve (AUC), predictive values (at a presumed 5% prevalence) and the likelihood ratios were determined via receiver operating curve (ROC) analysis using the Excel AnalyzeIT software.

**RESULTS**

**Performance Characteristics of cPass Neutralization Antibody Assay for COVID-19 Diagnosis**
Sensitivity was assessed based on testing 124 specimens collected at different time points after a positive COVID-19 diagnosis by RT-PCR. The assay showed an overall sensitivity of 76.6% (95% CI, 68.4% - 83.2%) post diagnosis by RT-PCR. As shown in Table 1, 23 out of 37 samples collected less than 7 days after being confirmed positive by RT-PCR and 4 out of 36 samples collected between 7-14 days tested negative by the cPass assay. For samples collected at greater than 14 days post-PCR, the sensitivity was 96.1% (95% CI, 94.9% - 97.3%). The clinical specificity, evaluated using 100 samples collected prior to the pandemic, showed 100% specificity (95% CI, 98.0%-100.0%) (Table 1). To evaluate the analytical specificity, samples positive for either other respiratory infections or that are positive for some of the common analytical interferences such as heterophile antibodies and rheumatoid factors were tested. Of the 92 samples tested, all were negative using the cPass neutralization antibody assay demonstrating no cross-reactivity and 100% (95% CI, 98.0%-100.0%) analytical specificity. The overall diagnostic ability of the assay to discriminate the positive and negative nAb presence was analyzed using ROC analysis. At the 30% cut-point established by the manufacturer, ROC analysis showed an area under the curve of 0.91 (95% CI, 0.87 - 0.96) with a statistical significance of \( P<.001 \) (Supplemental figure 1, see the supplemental digital content found at the end of the article, containing 1 figure and 2 tables). Estimates of seroprevalence prior to the availability of vaccines vary by location but tended to be around 5%\(^1\). At this prevalence, cPass demonstrated a 100% positive predictive value and 86% negative predictive value that correlated with the high specificity observed. At the manufacture derived cut-point of 30% inhibition, the assay showed a high positive likelihood ratio of >156.4 and a negative likelihood ratio of 0.24 (Table 1).

**Correlation between cPass Neutralization Antibody Assay and Live Virus Plaque Reduction Neutralization Test**

A panel of 28 RT-PCR confirmed COVID-19 positive sera with different levels of SARS-CoV-2 nAb were randomly chosen to compare with the conventional PRNT. Simple linear regression analysis showed a 0.76 coefficient of determination when the cPass neutralization antibody % inhibition results were compared against the PRNT50 titers (Figure 1A). Although the two methods exhibited a good
correlation quantitatively, cPass neutralization antibody test is designed and has received EUA approval for qualitative detection of SARS-CoV-2 nAbs. A qualitative comparison of the PRNT50 titers with that of the cPass neutralization antibody results for a positive and negative delineation showed an overall agreement of 97.4% (95% CI, 96.2% - 98.5%) (Supplemental table 1). There was only one out of 28 samples which was collected at an earlier time-point (8th day post positive RT-PCR confirmation) that did not corroborate with the PRNT50 results and tested negative using the cPass neutralization antibody assay but tested positive using the PRNT assay (Figures 1B and 1C). All the 10 healthy controls tested negative using the PRNT assay showed a 100% agreement with the cPass neutralization antibody assay (Figures 1B and 1C).

**Qualitative Comparison of cPass Neutralization Antibody Assay to Commercial SARS-CoV-2 Serology Assays**

At the manufacture-derived cut-points, the overall qualitative agreement between each of the IgG assays and cPass neutralization antibody assay was evaluated (Table 2). Due to sample volume limitations, not all samples were tested on each of the commercial assays. Out of the 117 PCR-confirmed COVID-19 positive samples evaluated, 83 were positive and 22 were negative (most of them collected at early time-points) on both Abbott and cPass assay. Among the 191 healthy controls and samples positive for infections other than COVID-19, 188 of them were negative on both the platforms giving an overall agreement of 95.1% (95% CI, 94.6% - 95.7%) (Table 2). Fifteen out of 308 samples (6 samples, <7 days, 4 samples, 7-14 days, 2 samples, >14 days collected post positive PCR-confirmation; 1 healthy control; 2 that were positive for infections other than COVID-19) had discordant results between cPass neutralization antibody assay and Abbott IgG assay. When comparing EUROIMMUN to cPass assay, of the 115 PCR-confirmed positive samples tested, 84 of them were positive and 23 of them were negative (most of them collected at early time-points) on both assays. Out of the 187 healthy controls and samples positive for infections other than COVID-19, 179 of them were negative on both the platforms giving an overall agreement of 94.7% (95% CI, 94.1% - 95.3%). Results from 16/302 samples (4 samples, <7 days, 2 samples, 7-14 days, 2 samples, >14 days collected post positive PCR-confirmation; 6 healthy controls;
that were positive for infections other than COVID-19) were discordant between cPass neutralization antibody assay and EUROIMMUN IgG assay. The Siemens IgG assay exhibited the best agreement with the cPass neutralization antibody results with only 7/293 results (4 samples, <7 days, 2 samples, >14 days collected post positive PCR-confirmation; 1 that were positive for infections other than COVID-19) being discordant between the two. Out of the 105 PCR-confirmed positive samples tested, 74 of them were positive and 24 of them were negative on both Siemens and cPass assay and out of the 189 healthy controls and samples positive for infections other than COVID-19, 188 of them were negative (most of them collected at early time-points) on both the platforms giving an overall agreement of 97.6% (97.2% - 98.0%) (Table 2).

**SARS-CoV-2 Commercial Serology Assays in the Prediction of nAb Presence as Detected by the cPass and PRNT Assays.**

To evaluate whether the commercial serology assays could be used to predict the SARS-CoV-2 neutralization activity as detected by the cPass assay, sensitivity and specificity was calculated using the qualitative cPass neutralization antibody results as the reference standard. At the manufacturer derived cut point, Abbott had a sensitivity of 94.3% (95% CI, 93.2% to 95.4%) and a specificity of 98.4% (95% CI, 98.0% to 98.8%) to predict the neutralization activity. EUROIMMUN had a sensitivity of 93.3% (95% CI, 94.1% to 95.3%) and a specificity of 95.7% (95% CI, 95.1% to 96.4%). Siemens exhibited the best diagnostic ability to predict the neutralization activity detected by the cPass assay with a sensitivity of 97.4% (95% CI, 96.6% to 98.2%) and a specificity of 99.5% (95% CI, 99.2% to 100.0%) (Table 2).

A similar analysis was performed using the PRNT assay positive and negative (cutoff, NT50 titer \( \geq 20 \)) results as the reference standard. The sensitivity and specificity of Abbott were 88.5% (95% CI, 85.5% to 91.4%) and 90.0% (95% CI, 85.6% to 99.5%) respectively (Supplemental table 2). Out of the 26 PCR-confirmed positive samples tested, 23 of them were positive on both Abbott and PRNT assay and out of the 10 healthy controls tested, 9 of them were negative on both the platforms. Four out of thirty-six results were discordant with an overall agreement of 88.9% (95% CI, 86.5% to 91.3%) between the Abbott and PRNT assay. EUROIMMUN predicted with a sensitivity and specificity of 88.9% (95% CI,
86.1% to 91.7%) and 100% respectively. EUROIMMUN had 24 out of 27 results that were concordant with the PRNT assay in the PCR positive category and there was zero discordance amongst the healthy controls adding up to an overall agreement of 91.4% (95% CI, 89.3% to 96.3%). Siemens predicted with a sensitivity of 96.0% (95% CI, 94.2% to 97.8%) and specificity of 100% respectively. Siemens and PRNT assay showed an overall agreement of 97.1% (95% CI, 95.9% to 98.4%) with only one discordant result in the PCR positive category (Supplemental table 2).

Quantitative Correlation between nAb Assays and Commercial SARS-CoV-2 IgG Serology Assays

To evaluate the quantitative correlation, nAb percent inhibition values derived from cPass assay or NT50 titers obtained from the PRNT assay were compared to the IgG signal to noise ratio acquired from the commercial SARS-CoV-2 IgG serology assays. The comparisons were conducted simultaneously in the 28 randomly selected RT PCR-confirmed COVID-19 positive samples using simple linear regression analysis (Figure 2A-2F). All three platforms included in our analysis showed a positive correlation to the nAb results. When the IgG results from the commercial assays were compared to NT50 titers from PRNT assay, Siemens (R² =0.39) displayed the lowest correlation, that was followed by EUROIMMUN (R² =0.57) and Abbott (R² =0.43). Comparison of the percent inhibition values obtained from the cPass assay to the IgG signals from the commercial serology assays showed the highest correlation with EUROIMMUN (R² =0.85) and comparable degrees of correlation with Abbott (R² =0.68) and Siemens (R² =0.63) (Figure 2A-2F).

Longitudinal Monitoring of Antibody Response in COVID-19 Patients

SARS-CoV-2 neutralization activity and IgG response detected using the cPass assay and commercial serology assays were longitudinally monitored in 5 RT PCR-confirmed SARS-CoV-2 patients for a range of 0 to 36 days per the availability of the results. The antibody response was low within the first week and steadily increased over time and generally peaked around 14-21 days across all platforms. Once elevated, neutralization activity plateaued in all 5 patients that was grossly comparable to the IgG response detected by the commercial serology assays. The only exception was patient 166 who
demonstrated a downward trend in the IgG response detected by the commercial serology assays after 17-29 days (Figure 3A-3D).

**DISCUSSION**

In the United States, there are over 200 SARS-CoV-2 serologic tests that are currently available, of which approximately 50 have obtained EUA. nAb is the only defined correlate to protective immunity to SARS-COV-2 induced either through natural infection or vaccination. Understanding the correlation between protective immunity and clinical protection is a required next phase in the vaccine regimen. A recent study has evaluated the nAb cut-off titers for 50% protection against detectable SARS-CoV-2 infection using data from seven vaccines available to date. Despite this, there are only a handful of published serology assays for the detection of SARS-CoV-2 nAbs. The challenges associated with the maintenance of the cell-based live virus assays, and lack of antibody thresholds correlating nAb antibody titers with the protective immunity have limited the availability of the nAb assays in the clinical labs. To date, only cPass assay has received EUA for the detection of nAbs. cPass is a simple, faster and scalable competitive ELISA-based assay for the detection of SARS-COV-2 nAbs.

In this study we assessed the performance characteristics of cPass neutralization antibody assay by comparing it to the gold standard PRNT assay in both qualitative and quantitative manner. A previous study had also confirmed the accuracy of cPass assay for differentiating nAb-positive and negative individuals by comparison to viral neutralization tests. Our data was consistent with the qualitative agreement observed between the cPass and PRNT assay used in this study. In our analysis, we also evaluated the quantitative relationship between the cPass percent inhibition neutralization values with the PRNT50 titers and our results demonstrated a good positive correlation. Additionally, unique to this study we evaluated whether the commercial IgG serology assays can predict the nAb activity with the same level of accuracy as the EUA approved cPass assay. Although the previous study described above compared the clinical sensitivity and specificity of cPass assay with several other commercial serology
assays, the characteristics were compared with reference to PCR-positivity and not in correlation with the nAbs to SARS-CoV-2. Our rigorous qualitative and quantitative comparisons across the commercial platforms targeted against different SARS-CoV-2 antigens confirmed the higher accuracy of cPass assay for the accurate detection of nAbs.

The coronavirus genome encodes four main structural proteins, the spike (S) protein, nucleocapsid (N) protein, membrane (M) protein, and the envelope (E) protein. The spike and the nucleocapsid proteins are the main immunogens. The S protein consists of two subunits, S1 which contains the Receptor Binding Domain (RBD) and N-terminal domain (NTD) and the second subunit is the S2. Neutralization antibodies are primarily generated against the S1, S2, and RBD domains of the SARS-CoV-2 spike protein and the cPass assay detects the nAb activity against the RBD region. We used a laboratory-developed PRNT assay in a randomly selected PCR-confirmed samples to compare with the cPass assay. The cPass assay has a manufacturer-established cut-point of 30% inhibition rate (neutralization activity) that has been correlated to an NT50 neutralization titer of 1:20. At this cut-point our data revealed a good positive correlation and an excellent qualitative agreement with the PRNT assay, also with an established NT50 neutralization titer of 1:20 as the cut-point. Similar but a slightly better correlation between cPass and live virus nAb results has been reported before which could be attributed to the differences in the live virus assay methodology and the lack of precision common to PRNT assays as a result of the subjective nature of scoring the results.

The sensitivity of the cPass assay for the detection of nAb was the highest at time points >14 days post positive-PCR confirmation. Although samples collected at <7 days following the PCR test had 23 out of 124 positive PCR-confirmed specimens that tested negative, 81 out of the 87 positive PCR-confirmed specimens collected at >7 days following a PCR possessed positive neutralization activity. cPass identified six PCR-positive samples as negative; 1 of them was negative in all three platforms, 3 other samples coincided with their negative classification on Siemens and EUROIMMUN but was positive on Abbott and the remaining 2 samples were discordant between platforms. We note that the 4 patient specimens who did not have a neutralization activity were collected early in the disease process.
(7-14 days) when there was probably a low to no seroconversion. These sensitivity data for the cPass assay using PCR results as the reference were largely comparable to the sensitivities observed on the commercially available Abbott, Siemens and EUROIMMUN IgG assays, previously published by our group\textsuperscript{26}.

It has been hypothesized that the IgG serology assays targeting the RBD domain are better able to predict the neutralization activity against the SARS-CoV-2 virus\textsuperscript{9}. Our data generally supported this hypothesis. Our data revealed not much differences between Abbott’s (N) and EUROIMMUN’s (S1) agreement with the cPass neutralization antibody results, however, Siemens (RBD) assay exhibited the best agreement and had the highest sensitivity to predict the neutralization activity. The plausible reason could be the involvement of the same target antigens (RBD) in both the cPass neutralization antibody and the Siemens IgG assays. It is interesting to note that Abbott assay which targets nucleocapsid exhibited an agreement with the nAb results in a similar manner to that of EUROIMMUN and Siemens, which target spike and RBD components, the major elicitors of the nAbs. This is likely due to the similar kinetics and early seroconversion of anti-nucleocapsid and anti-RBD proteins in response to SARS-COV-2 infection. It has been reported in the literature that the detection of both RBD and the nucleocapsid protein is more sensitive than the detection of S1 or S2, respectively\textsuperscript{27}. Although RBD is a part of S1 protein, the differences observed in the anti-S1 and anti-RBD responses may be attributed to the presence of cryptic epitopes within the RBD region of S1\textsuperscript{28}. Our longitudinal follow-up on select patients revealed an increasing trend in the nAb response for the first two weeks post-PCR confirmation, which plateaued eventually. This was consistent to the observations made by other groups that reported a variable but increasing nAb response and a plateauing 2 weeks post-symptom onset\textsuperscript{29-31}. Although many have reported the trend and kinetics of the SARS-COV-2 antibody response in the short-term, the long-term kinetics and durability of the nAbs is still in question\textsuperscript{32-34}.

Neutralization antibodies represent only a subset of antibodies produced and not all binding antibodies have the blocking ability. Currently, manufacturers such as Diasorin and Siemens are moving in the direction of associating the IgG (binding and blocking) positive results detected in their assay with
a nAb (blocking) claim. We calculated the sensitivity and specificity of the commercial IgG serology assays in the prediction of the nAb activity using cPass results as reference. Noticeably, majority of samples that were collected >14 days post-PCR confirmation and detected with antibodies by the commercial IgG serology assays had a positive nAb presence (>97% sensitivity). Similarly, majority of the negative IgG results in the healthy donors acquired from Abbott and Siemens assay correlated with negative neutralization activity (>99% specificity); EUROIMMUN had a slightly lower specificity (~93%). Samples with nAb that were discordant with the IgG results largely represented samples that were closer to the cut-off. Overall, IgG serology results showed a high level of association with the presence and absence of nAbs, as detected by the cPass assay.

However, when IgG serology results were correlated with the PRNT assay, the sensitivity for the detection of the positive NT50 titers were largely variable; Siemens exhibited the highest sensitivity (>97%) compared to Abbott and EUROIMMUN. Furthermore, PRNT50 neutralization titers or percent inhibition values acquired from cPass assay in SARS-CoV-2 PCR-confirmed positive patients correlated with the corresponding signal to noise ratio on the Abbott, EUROIMMUN and Siemens platforms at varying degrees in a poor to modest manner. While anti-S1 IgG results from EUROIMMUN exhibited a poor qualitative agreement with the nAb presence, the IgG signals showed the highest quantitative correlation with the nAb results. This is likely due to the linear characteristics of this platform. Overall, IgG signals generated by the serology platforms displayed varying degrees of quantitative correlation with the nAb antibody results. One other critical factor to consider is the differences in the antibody classes detected by these assays. Neutralization antibody assays are isotype-independent, and the results are reflective of the combined activity of all nAbs in a sample, whereas the serology assays are IgG-specific. This could likely cause differences in the mechanism of detection and in assay signal output relating to the antibody concentrations.

This study is limited due to the lack of clinical data to correlate the disease severity with the magnitude and kinetics of the nAb response. Additionally, our study cohort did not include samples that were collected at longer time-points from initial COVID-19 diagnosis. However, understanding the long-
term kinetics of the nAbs levels and its correlation with disease severity is beyond the scope of this study. Due to limited specimen volumes, a few samples were not available for comparison across all commercial assays. Despite these limitations, our results were consistent with the manufacturer’s performance claims and with the previous studies that had evaluated the accuracy of this cPass ELISA-based neutralization antibody assay\textsuperscript{8,16,22}.

In conclusion, the cPass neutralization antibody assay demonstrated excellent performance characteristics and correlated well not only qualitatively but also quantitatively with PRNT titers, which is the gold standard. The IgG signal noise output on the commercially available serology platforms, Abbott, EUROIMMUN and Siemens had varying degrees of association with the nAb signals. However, positive IgG results by the commercial serology assays exhibited a close qualitative agreement with SARS-CoV-2 neutralization activity, making them a practical alternative in the absence of the cPass neutralization antibody assay.

More studies are required to adequately assess the protection against infection and longevity of the post-vaccination response; nevertheless, nAbs are currently viewed as the first line of protective immunity\textsuperscript{5}. Although the IgG serology assays exhibited the ability to predict the neutralization activity against the SARS-CoV-2 virus in a reasonable manner, these are indirect approaches and lack the capacity to distinguish the binding from the nAbs. The cPass neutralization antibody assay offers the most direct and specific format for the detection of the neutralization function with capabilities for scalability, high-throughput and faster turnaround times. The accurate and specific detection of nAbs using easy to measure assays like cPass assay may have a wide range of applications in population monitoring post infection and vaccination, and in the screening of donors for COVID-19 convalescent plasma therapy. Despite these advantages, emerging SARS-COV-2 variants raise concerns about resistance to nAbs in response to infections and vaccines\textsuperscript{35-37}. Mutations of concern have been reported in the spike protein with hotspots specifically in the RBD domain\textsuperscript{36,38}. Further studies will be required to understand the ability of the assay to quantify the neutralization activity of antibodies targeted to the variant specific- RBD regions.
FIGURE LEGENDS

Figure 1: Comparison of cPass neutralization antibody assay with viral PRNT assay. A. Percent inhibition values from the cPass assay were plotted against the log NT50 neutralization titers and the correlation coefficient was calculated. B-C. Qualitative agreement between the cPass and PRNT assay, grey dot represent the discordant sample between the two assays. Dotted line denotes the cut-off to delineate the positive and negative for each assay. Plaque Reduction Neutralization Test (PRNT).

Figure 2: Correlation between PRNT or cPass neutralization antibody assay and the commercial IgG serology assays.

The log ratio of the signal to calibrator (S/Co) for each commercial assay was plotted against the percent inhibition values from the cPass neutralization antibody assay or the NT50 neutralization titers and the correlation coefficients were calculated for each combination. A. PRNT (log NT50) versus Abbott (log S/Co), B. PRNT (log NT50) versus EUROIMMUN (log S/Co), C. PRNT (log NT50) versus Siemens (log S/Co), D. cPass % inhibition versus Abbott (log S/Co), E. cPass % inhibition versus EUROIMMUN (log S/Co), and F. cPass % inhibition versus Siemens (log S/Co). Plaque Reduction Neutralization Test (PRNT).

Figure 3: SARS-CoV-2 Antibody Kinetics Percent inhibition values or the ratio of the signal to calibrator (S/Co) are plotted relative to days post positive RT-PCR for A. cPass neutralization antibody assays % inhibiton versus time post-RT-PCR. B. Abbott (S/Co) versus time post-RT-PCR., C. EUROIMMUN (S/Co) versus time post-RT-PCR., and D. Siemens (S/Co) versus time post-RT-PCR.

Each plotted line represents an individual patient and are plotted using the same color for all graphs.
REFERENCES

1. Zhao J, Yuan Q, Wang H, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019. *Clin Infect Dis.* 2020;71(16):2027-2034.

2. Petherick A. Developing antibody tests for SARS-CoV-2. *Lancet.* 2020;395(10230):1101-1102.

3. Theel ES, Slev P, Wheeler S, Couturier MR, Wong SJ, Kadkhoda K. The role of antibody testing for SARS-CoV-2: is there one? *J Clin Microbiol.* 2020;58(8):e00797-20.

4. Liu L, Wang P, Nair MS, et al. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. *Nature.* 2020;584(7821):450-456.

5. Lin Q, Zhu L, Ni Z, Meng H, You L. Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection. *J Microbiol Immunol Infect.* 2020;53(5):821-822.

6. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. *Euro Surveill.* 2020;25(16):2000421.

7. Okba NMA, Muller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2-specific antibody responses in coronavirus disease 2019 patients. *Emerg Infect Dis.* 2020;26(7):1478-1488.

8. Tan CW, Chia WN, Qin X, et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol.* 2020;38(9):1073-1078.

9. Tang MS, Case JB, Franks CE, et al. Association between SARS-CoV-2 neutralizing antibodies and commercial serological assays. [Published online ahead of print, September 7. 2020]. *Clin Chem.* doi:10.1093/clinchem/hvaa211.

10. Suhandynata RT, Hoffman MA, Huang D, et al. Commercial serology assays predict neutralization activity against SARS-CoV-2. *Clin Chem.* 2021;67(2):404-414.

11. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 seroprevalence in the US as of September 2020. *JAMA Intern Med.* 2021;181(4):450-460.
12. Food and Drug Administration. EUA Authorized Serology Test Performance. 2021. 
https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-
medical-devices/eua-authorized-serology-test-performance. Accessed 04/02/2021.

13. Addetia A, Crawford KHD, Dingens A, et al. Neutralizing antibodies correlate with protection
from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. *J Clin Microbiol.*
2020;58(11):e02107-20.

14. Huang AT, Garcia-Carreras B, Hitchings MDT, et al. A systematic review of antibody mediated
immunity to coronaviruses: antibody kinetics, correlates of protection, and association of antibody
responses with severity of disease. Preprint. *medRxiv.* Posted April 17 2020. 
doi:10.1101/2020.04.14.20065771.

15. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly predictive of
immune protection from symptomatic SARS-CoV-2 infection. [Published online ahead of print, May 17,
2021]. *Nat Med.* doi:10.1038/s41591-021-01377-8.

16. Taylor SC, Hurst B, Charlton CL, et al. A new SARS CoV-2 dual purpose serology test: highly
accurate infection tracing and neutralizing antibody response detection. [Published online ahead of print,
March 19, 2021]. *J Clin Microbiol.* doi:10.1128/jcm.02438-20.

17. Garcia-Beltran WF, Lam EC, Astudillo MG, et al. COVID-19-neutralizing antibodies predict
disease severity and survival. *Cell.* 2021;184(2):476-488.e11.

18. Ng DL, Goldgof, G. M.,Shy, et al. SARS-CoV-2 seroprevalence and neutralizing activity in
donor and patient blood. *Nat Commun.* 2020;11(1):4698.

19. Meyer B, Reimerink J, Torriani G, et al. Validation and clinical evaluation of a SARS-CoV-2
surrogate virus neutralisation test (sVNT). *Emerg Microbes Infect.* 2020;9(1):2394-2403.

20. Johnson M, Wagstaffe HR, Gilmour KC, et al. Evaluation of a novel multiplexed assay for
determining IgG levels and functional activity to SARS-CoV-2. *J Clin Virol.* 2020;130:104572.
21. Zhang YV, Wiencek J, Meng QH, et al. AACC practical recommendations for implementing and interpreting SARS-CoV-2 EUA and LDT serologic testing in clinical laboratories. [Published online ahead of print March 24, 2021]. Clin Chem. doi:10.1093/clinchem/hvab051.

22. GenScript. cPass SARS-CoV-2 Neutralization Antibody Detection Kit. 2020. https://www.fda.gov/media/143583/download. Accessed 09/29/2020.

23. Meyer B, Drosten C, Müller MA. Serological assays for emerging coronaviruses: challenges and pitfalls. Virus Res. 2014;194:175-83.

24. Shi J, Han D, Zhang R, Li J, Zhang R. Molecular and serological assays for SARS-CoV-2: Insights from genome and clinical characteristics. Clin Chem. 2020;66(8):1030-1046. doi:10.1093/clinchem/hvaa122

25. Luchsinger LL, Ransegno BP, Jin DK, et al. Serological assays estimate highly variable SARS-CoV-2 neutralizing antibody activity in recovered COVID-19 patients. J Clin Microbiol. 2020;58(12):e02005-20

26. Rychert J, Couturier MR, Elgort M, et al. Evaluation of three SARS CoV-2 IgG antibody assays and correlation with neutralizing antibodies. J Appl Lab Med. 2021;6(3):614-624.

27. Brochot E, Demey B, Touzé A, et al. Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals. Front Microbiol. 2020;11:584251.

28. Yuan M, Wu NC, Zhu X, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science. 2020;368(6491):630-633.

29. Fafi-Kremer S, Bruel T, Madec Y, et al. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine. 2020;59:102915.

30. Wu F, Liu M, Wang A, et al. Evaluating the association of clinical characteristics with neutralizing antibody levels in patients who have recovered from mild COVID-19 in Shanghai, China. JAMA Intern Med. 2020;180(10):1356-1362.

31. Liu L, To KK, Chan KH, et al. High neutralizing antibody titer in intensive care unit patients with COVID-19. Emerg Microbes Infect. 2020;9(1):1664-1670.
32. Wang Y, Zhang L, Sang L, et al. Kinetics of viral load and antibody response in relation to COVID-19 severity. *J Clin Invest*. 2020;130(10):5235-5244.

33. Lynch KL, Whitman JD, Lacanienta NP, et al. Magnitude and kinetics of anti-severe acute respiratory syndrome coronavirus 2 antibody responses and their relationship to disease severity. *Clin Infect Dis*. 2021;72(2):301-308.

34. Wang K, Long QX, Deng HJ, et al. Longitudinal dynamics of the neutralizing antibody response to SARS-CoV-2 infection. [Published online ahead of print August 3, 2020]. *Clin Infect Dis*. doi:10.1093/cid/ciaa1143.

35. Volz E MS, Chand M, Barrett JC, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data. Preprint. *medRxiv*. Posted January 4, 2021. doi:10.1101/2020.12.30.20249034.

36. Tegally H WE, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-d) lineage with multiple spike mutations in South Africa. Preprint. *medRxiv*. Posted December 22, 2020. doi:10.1101/2020.12.21.20248640.

37. Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Preprint. *medRxiv*. doi:10.1101/2020.12.24.20248822.

38. O'Toole A, Hill V, Pybus OG, et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-Y2. 2021. https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592. Accessed 04/02/2021.
Table 1. Performance characteristics of the cPass neutralization antibody assay in the PCR-verified positive and negative cohort.

| Cohort                      | Positive cPass (≥30%) | Negative cPass (<30%) | Sensitivity % (95% CI) | Specificity % (95% CI) | Positive Likelihood Ratio | Negative Likelihood Ratio | PPV % at 5% Prevalence | NPV % at 5% Prevalence |
|-----------------------------|-----------------------|-----------------------|------------------------|------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Total (n=316)               | 95/124                | 192/192               | 76.6 (68.4-83.2)       | 100.0 (98.0-100.0)     | >156.4                   | 0.24                     | 100                      | 86                       |
| Positive (n=124)            |                       |                       |                        |                        |                          |                          |                          |                          |
| < 7 days post-PCR + (n=37)  | 14/37                 | 23/37                 | 37.8 (32.2-43.5)       |                        |                          |                          |                          |                          |
| 7-14 days post-PCR + (n=36) | 32/36                 | 4/36                  | 88.9 (86.5-91.3)       |                        |                          |                          |                          |                          |
| > 14 days post-PCR + (n=51) | 49/51                 | 2/51                  | 96.1 (94.9-97.3)       |                        |                          |                          |                          |                          |
| Healthy (n=100)             | 0/100                 | 100/100               |                        | 100.0 (98.0-100.0)     |                          |                          |                          |                          |
| Other infections (n=92)     | 0/92                  | 92/92                 |                        | 100.0 (98.0-100.0)     |                          |                          |                          |                          |

PPV and NPV denotes positive and negative predictive values respectively and is calculated in a presumed 5% prevalence setting. PCR, polymerase chain reaction.
Table 2. Performance characteristics of the commercial IgG serology assays in predicting the neutralizing antibody (nAb) activity detected by the cPass assay.

| Cohort          | Positive cPass (≥30%) | Negative cPass (<30%) | Overall agreement % (95% CI) | Sensitivity % (95% CI) | Specificity % (95% CI) |
|-----------------|-----------------------|-----------------------|-----------------------------|------------------------|------------------------|
| **Abbott (Cut-off: >1.4)** | Positive | Negative |                           |                        |                        |
| Total (n=308)   | 83/88 | 210/220 | 95.1 (94.6-95.7) | 94.3 (93.2-95.4) | 98.4 (98.0-98.8) |
| Positive (n=117) | 10/13 | 20/23 | 76.9 (71.1-82.8) |                        |                        |
| < 7 days post-PCR + (n=36) | 29/30 | 1/4 | 96.7 (95.2-98.1) |                        |                        |
| 7-14 days post-PCR + (n=34) | 44/45 | 1/2 | 97.8 (96.8-98.8) |                        |                        |
| > 14 days post-PCR + (n=47) | 0/100 | 99/100 | 99.0 (98.6-99.4) |                        |                        |
| Healthy (n=100) | 0/100 | 99/100 |                        |                        |                        |
| Other infections (n=91) | 0/91 | 89/91 | 97.8 (97.1-98.5) |                        |                        |
| **EUROIMMUN (Cut-off: >1.1)** | Positive | Negative |                           |                        |                        |
| Total (n=302)   | 84/90 | 202/212 | 94.7 (94.1-95.3) | 93.3 (94.1-95.3) | 95.7 (95.1-96.4) |
| Positive (n=115) | 10/13 | 19/20 | 76.9 (71.1-82.8) |                        |                        |
| < 7 days post-PCR + (n=33) | 29/31 | 4/4 | 93.6 (91.5-95.5) |                        |                        |
| 7-14 days post-PCR + (n=35) | 45/46 | 0/1 | 97.8 (96.9-98.8) |                        |                        |
| > 14 days post-PCR + (n=47) | 0/96 | 90/96 | 93.8 (92.6-94.9) |                        |                        |
| Healthy (n=96) | 0/96 | 90/96 |                        |                        |                        |
| Other infections (n=91) | 0/89 | 89/91 | 97.8 (97.1-98.5) |                        |                        |
| **Siemens (Cut-off: >1.0)** | Positive | Negative |                           |                        |                        |
| Total (n=293)   | 74/76 | 212/217 | 97.6 (97.2-98.0) | 97.4 (96.6-98.2) | 99.5 (99.2-100) |
| Positive (n=105) | 8/10 | 21/23 | 80.0 (73.8-86.2) | 100.0 (98.0-100.0) | 100.0 (98.0-100.0) |
| < 7 days post-PCR + (n=33) | 27/27 | 3/3 | 100.0 (98.0-100.0) |                        |                        |
| 7-14 days post-PCR + (n=30) | 39/39 | 0/2 | 100.0 (98.0-100.0) |                        |                        |
| > 14 days post-PCR + (n=41) | 0/100 | 100/100 | 100.0 (98.0-100.0) |                        |                        |
| Healthy (n=100) | 0/100 | 100/100 |                        |                        |                        |
| Other infections (n=89) | 0/88 | 88/89 | 98.9 (98.4-99.4) |                        |                        |

Sensitivities and specificities were determined using cPass neutralization antibody results as the reference. The overall agreement is the proportion of concordant results between the cPass neutralization antibody assay and each of the commercial IgG assays. PCR, polymerase chain reaction.
Supplemental Digital Content, containing one figure and two tables. The Supplemental Digital Content was not copyedited by Archives of Pathology & Laboratory Medicine.

Supplemental figure 1

Supplemental figure 1. ROC analysis for the GenScript cPass neutralization assays using the PCR results as the reference standard.

| Area under the curve (95%CI) | Standard Error | P Value |
|------------------------------|----------------|---------|
| 0.91 (0.87-0.96)             | 0.023          | $P<.001$ |
Supplementary table 1. Agreement between GenScript cPass neutralization antibody assay and PRNT NT50 assay. The overall agreement is the proportion of concordant results between GenScript cPass neutralization antibody assay and PRNT NT50 assay. Plaque Reduction Neutralization Test (PRNT).

| Cohort                  | Positive cPass (≥30%) | Negative cPass (<30%) | Overall Agreement % (95%CI) | Sensitivity % (95%CI) | Specificity % (95%CI) |
|-------------------------|-----------------------|------------------------|-----------------------------|-----------------------|-----------------------|
| PRNT NT50 (Cut-off:≥20) | Positive              | Negative               |                             |                       |                       |
| PCR + (n=28)            | 27/28                 | 0/28                   | 97.4 (96.2-98.5)            | 96.4 (94.9-98.0)      |                       |
| Healthy (n=10)          | 0/10                  | 10/10                  |                             |                       | 100 (98.0-100.0)      |
Supplementary table 2. Performance characteristics of the commercial serology assays in predicting the neutralizing antibody (nAb) activity detected by the PRNT NT50 assay. Plaque Reduction Neutralization Test (PRNT).

| Cohort         | Positive PRNT (NT50≥20) | Negative PRNT (NT50<20) | Overall Agreement % (95%CI) | Sensitivity % (95%CI) | Specificity % (95%CI) |
|---------------|-------------------------|-------------------------|-----------------------------|-----------------------|-----------------------|
| **Abbott (Cut-off:>1.4)** |                         |                         |                             |                       |                       |
| PCR + (n=26)  | 23/26                   | 0/26                    | 88.9 (86.5-91.3)            | 88.5 (85.5-91.4)      |                       |
| Healthy (n=10)| 0/10                    | 9/10                    |                             |                       | 90.0 (85.6-99.5)      |
| **EUROIMMUN (Cut-off>1.1)** |                     |                         |                             |                       |                       |
| PCR + (n=27)  | 24/27                   | 0/27                    | 91.4 (89.3-96.3)            | 88.9 (86.1-91.7)      |                       |
| Healthy (n=8) | 0/8                     | 8/8                     |                             |                       | 100 (98.0-100.0)      |
| **Siemens (Cut-off:>1.0)** |                     |                         |                             |                       |                       |
| PCR + (n=25)  | 24/25                   | 0/25                    | 97.1 (95.9-98.4)            | 96.0 (94.2-97.8)      |                       |
| Healthy (n=10)| 0/10                    | 10/10                   |                             |                       | 100 (98.0-100.0)      |